Solid preclinical evidence had been provided to support multiple mechanisms of action for TLR-9 agonists, either on tumor, endothelial and immune cells, suggesting that this class of agent may play an anti-tumor role, both directly on cancer cells and indirectly on the tumor microenvironment. Here, TLR9 is linked to cancer.